Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 2, 2013

View Archived Issues

Merck KGaA announces new partnerships with Israeli companies

Inhibition of PDE10 shows promise in lung orthotopic mouse model

Design of the first animal model of spontaneous atherothrombotic occlusion due to plaque erosion

Results reported from phase I study of a double-mutant enterotoxin for traveler's diarrhea

Cognition Therapeutics' Abeta oligomer receptor antagonists for Alzheimer's disease

Report on development of peptides for inhibiting Abeta aggregation in Alzheimer's disease

Lycera Corp. presents new ROR-gamma agonists

Merck & Co. synthesizes novel alpha-type CGRP receptor antagonists

DBPR-211 as a potent and orally active CB1 antagonist in vivo

Novel MetAP 2 inhibitors patented by Zalgen for obesity

Piramal Enterprises presents novel agents for cancer

BPR-000A leads to reductions in tumor size in vivo

Pfizer to begin phase I study of PF-06263276 in healthy subjects

Japanese researchers invent novel MCH-R1 antagonists for obesity

Genentech enrolls patients in phase II trial of MHAA-4549-A

Alchemia provides update on phase III HA-irinotecan trial

Ferrer and Janus Developments create new strategic alliance

Daiichi Sankyo launches new formulation of natural tetrahydrobiopterin agent

GlaxoSmithKline receives positive CHMP opinion for two-dose schedule of Cervarix

Collaboration to generate new cancer drugs in the field of epigenetics

Navidea to collaborate with UAB on study of RIGS monoclonal antibody targeting agent

Sareum signs codevelopment agreement with HMUBEC

InnaVirVax initiates phase II study of VAC-3S with ART in HIV-1

Cell Therapeutics receives sales milestone payment for Trisenox

PNP Therapeutics advances phase I trial in head and neck cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...